Which has stronger earnings and valuation, NVAX or MRNA?

Novavax has higher earnings, but lower revenue than Moderna. Novavax is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $1.12B 1.30 $440.30M -$0.58 N/A Moderna $1.94B 10.19 -$2.82B -$8.15 N/A

Is NVAX or MRNA more profitable?

Novavax has a net margin of -14.73% compared to Moderna's net margin of -143.55%. Novavax's return on equity of -14.82% beat Moderna's return on equity. Company Net Margins Return on Equity Return on Assets Novavax -14.73% -14.82% 1.23% Moderna -143.55% -26.64% -19.32%

Does the media favor NVAX or MRNA?

In the previous week, Moderna had 11 more articles in the media than Novavax. MarketBeat recorded 19 mentions for Moderna and 8 mentions for Novavax. Moderna's average media sentiment score of 0.57 beat Novavax's score of 0.36 indicating that Moderna is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Moderna 11 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Which has stronger valuation and earnings, OCGN or NVAX?

Novavax has higher revenue and earnings than Ocugen. Novavax is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ocugen $4.41M 92.88 -$67.85M -$0.24 N/A Novavax $1.12B 1.30 $440.30M -$0.58 N/A

Is OCGN or NVAX more profitable?

Novavax has a net margin of -14.73% compared to Ocugen's net margin of -1,192.18%. Novavax's return on equity of -14.82% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Ocugen -1,192.18% -127,987.80% -135.48% Novavax -14.73% -14.82% 1.23%

Which has better earnings & valuation, AZN or NVAX?

Astrazeneca has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Astrazeneca $60.44B 4.59 $10.23B $6.66 26.85 Novavax $1.12B 1.30 $440.30M -$0.58 N/A

Is AZN or NVAX more profitable?

Astrazeneca has a net margin of 17.19% compared to Novavax's net margin of -14.73%. Astrazeneca's return on equity of 30.86% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Astrazeneca 17.19% 30.86% 12.68% Novavax -14.73% -14.82% 1.23%

Does the media prefer AZN or NVAX?

In the previous week, Astrazeneca had 5 more articles in the media than Novavax. MarketBeat recorded 13 mentions for Astrazeneca and 8 mentions for Novavax. Astrazeneca's average media sentiment score of 0.55 beat Novavax's score of 0.36 indicating that Astrazeneca is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Astrazeneca 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novavax 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, NVAX or JNJ?

Johnson & Johnson has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $1.12B 1.30 $440.30M -$0.58 N/A Johnson & Johnson $94.19B 6.15 $26.80B $8.65 27.81

Is NVAX or JNJ more profitable?

Johnson & Johnson has a net margin of 21.83% compared to Novavax's net margin of -14.73%. Johnson & Johnson's return on equity of 32.60% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Novavax -14.73% -14.82% 1.23% Johnson & Johnson 21.83% 32.60% 13.29%

Does the media favor NVAX or JNJ?

In the previous week, Johnson & Johnson had 110 more articles in the media than Novavax. MarketBeat recorded 118 mentions for Johnson & Johnson and 8 mentions for Novavax. Johnson & Johnson's average media sentiment score of 1.19 beat Novavax's score of 0.36 indicating that Johnson & Johnson is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Johnson & Johnson 88 Very Positive mention(s) 14 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 4 Very Negative mention(s) Positive

Which has preferable valuation & earnings, NVAX or PFE?

Pfizer has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novavax $1.12B 1.30 $440.30M -$0.58 N/A Pfizer $62.58B 2.39 $7.77B $1.31 19.99

Is NVAX or PFE more profitable?

Pfizer has a net margin of 11.83% compared to Novavax's net margin of -14.73%. Pfizer's return on equity of 19.44% beat Novavax's return on equity. Company Net Margins Return on Equity Return on Assets Novavax -14.73% -14.82% 1.23% Pfizer 11.83% 19.44% 8.41%

Does the media prefer NVAX or PFE?

In the previous week, Pfizer had 89 more articles in the media than Novavax. MarketBeat recorded 97 mentions for Pfizer and 8 mentions for Novavax. Pfizer's average media sentiment score of 1.02 beat Novavax's score of 0.36 indicating that Pfizer is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novavax 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Pfizer 65 Very Positive mention(s) 8 Positive mention(s) 11 Neutral mention(s) 10 Negative mention(s) 2 Very Negative mention(s) Positive

Novavax (NVAX) Competitors

$8.88 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$8.93 +0.05 (+0.56%)

As of 06/12/2026 07:48 PM Eastern

Compare

NVAX vs. MRNA, OCGN, AZN, JNJ, and PFE

Should you buy Novavax stock or one of its competitors? MarketBeat compares Novavax with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Novavax include Moderna (MRNA), Ocugen (OCGN), Astrazeneca (AZN), Johnson & Johnson (JNJ), and Pfizer (PFE).

How does Novavax compare to Moderna?

Novavax (NASDAQ:NVAX) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

53.0% of Novavax shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 1.6% of Novavax shares are owned by insiders. Comparatively, 10.8% of Moderna shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Moderna had 11 more articles in the media than Novavax. MarketBeat recorded 19 mentions for Moderna and 8 mentions for Novavax. Moderna's average media sentiment score of 0.57 beat Novavax's score of 0.36 indicating that Moderna is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Moderna	11 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

Novavax has higher earnings, but lower revenue than Moderna. Novavax is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.30	$440.30M	-$0.58	N/A
Moderna	$1.94B	10.19	-$2.82B	-$8.15	N/A

Novavax presently has a consensus price target of $12.13, suggesting a potential upside of 36.54%. Moderna has a consensus price target of $36.60, suggesting a potential downside of 26.67%. Given Novavax's stronger consensus rating and higher possible upside, equities research analysts clearly believe Novavax is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

Novavax has a beta of 2.45, indicating that its share price is 145% more volatile than the broader market. Comparatively, Moderna has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market.

Novavax has a net margin of -14.73% compared to Moderna's net margin of -143.55%. Novavax's return on equity of -14.82% beat Moderna's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
Moderna	-143.55%	-26.64%	-19.32%

Summary

Novavax beats Moderna on 9 of the 16 factors compared between the two stocks.

How does Novavax compare to Ocugen?

Ocugen (NASDAQ:OCGN) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

Novavax has higher revenue and earnings than Ocugen. Novavax is trading at a lower price-to-earnings ratio than Ocugen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ocugen	$4.41M	92.88	-$67.85M	-$0.24	N/A
Novavax	$1.12B	1.30	$440.30M	-$0.58	N/A

In the previous week, Novavax had 7 more articles in the media than Ocugen. MarketBeat recorded 8 mentions for Novavax and 1 mentions for Ocugen. Ocugen's average media sentiment score of 1.89 beat Novavax's score of 0.36 indicating that Ocugen is being referred to more favorably in the media.

Company	Overall Sentiment
Ocugen	Very Positive
Novavax	Neutral

10.3% of Ocugen shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 4.0% of Ocugen shares are held by company insiders. Comparatively, 1.6% of Novavax shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Novavax has a net margin of -14.73% compared to Ocugen's net margin of -1,192.18%. Novavax's return on equity of -14.82% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ocugen	-1,192.18%	-127,987.80%	-135.48%
Novavax	-14.73%	-14.82%	1.23%

Ocugen presently has a consensus target price of $9.50, suggesting a potential upside of 685.12%. Novavax has a consensus target price of $12.13, suggesting a potential upside of 36.54%. Given Ocugen's stronger consensus rating and higher possible upside, equities analysts clearly believe Ocugen is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10

Ocugen has a beta of 2.2, meaning that its stock price is 120% more volatile than the broader market. Comparatively, Novavax has a beta of 2.45, meaning that its stock price is 145% more volatile than the broader market.

Summary

Novavax beats Ocugen on 9 of the 16 factors compared between the two stocks.

How does Novavax compare to Astrazeneca?

Astrazeneca (NYSE:AZN) and Novavax (NASDAQ:NVAX) are related companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Astrazeneca has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Astrazeneca	$60.44B	4.59	$10.23B	$6.66	26.85
Novavax	$1.12B	1.30	$440.30M	-$0.58	N/A

Astrazeneca has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market. Comparatively, Novavax has a beta of 2.45, indicating that its stock price is 145% more volatile than the broader market.

20.4% of Astrazeneca shares are held by institutional investors. Comparatively, 53.0% of Novavax shares are held by institutional investors. 1.6% of Novavax shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Astrazeneca presently has a consensus target price of $205.33, indicating a potential upside of 14.85%. Novavax has a consensus target price of $12.13, indicating a potential upside of 36.54%. Given Novavax's higher possible upside, analysts plainly believe Novavax is more favorable than Astrazeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Astrazeneca	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10

In the previous week, Astrazeneca had 5 more articles in the media than Novavax. MarketBeat recorded 13 mentions for Astrazeneca and 8 mentions for Novavax. Astrazeneca's average media sentiment score of 0.55 beat Novavax's score of 0.36 indicating that Astrazeneca is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Astrazeneca	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novavax	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Astrazeneca has a net margin of 17.19% compared to Novavax's net margin of -14.73%. Astrazeneca's return on equity of 30.86% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Astrazeneca	17.19%	30.86%	12.68%
Novavax	-14.73%	-14.82%	1.23%

Summary

Astrazeneca beats Novavax on 12 of the 16 factors compared between the two stocks.

How does Novavax compare to Johnson & Johnson?

Novavax (NASDAQ:NVAX) and Johnson & Johnson (NYSE:JNJ) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

Johnson & Johnson has a net margin of 21.83% compared to Novavax's net margin of -14.73%. Johnson & Johnson's return on equity of 32.60% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
Johnson & Johnson	21.83%	32.60%	13.29%

Johnson & Johnson has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Johnson & Johnson, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.30	$440.30M	-$0.58	N/A
Johnson & Johnson	$94.19B	6.15	$26.80B	$8.65	27.81

Novavax has a beta of 2.45, meaning that its stock price is 145% more volatile than the broader market. Comparatively, Johnson & Johnson has a beta of 0.26, meaning that its stock price is 74% less volatile than the broader market.

Novavax presently has a consensus price target of $12.13, suggesting a potential upside of 36.54%. Johnson & Johnson has a consensus price target of $253.04, suggesting a potential upside of 5.18%. Given Novavax's higher possible upside, analysts clearly believe Novavax is more favorable than Johnson & Johnson.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10
Johnson & Johnson	0 Sell rating(s)	7 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.74

53.0% of Novavax shares are held by institutional investors. Comparatively, 69.6% of Johnson & Johnson shares are held by institutional investors. 1.6% of Novavax shares are held by insiders. Comparatively, 0.2% of Johnson & Johnson shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Johnson & Johnson had 110 more articles in the media than Novavax. MarketBeat recorded 118 mentions for Johnson & Johnson and 8 mentions for Novavax. Johnson & Johnson's average media sentiment score of 1.19 beat Novavax's score of 0.36 indicating that Johnson & Johnson is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Johnson & Johnson	88 Very Positive mention(s)	14 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	4 Very Negative mention(s)	Positive

Summary

Johnson & Johnson beats Novavax on 13 of the 16 factors compared between the two stocks.

How does Novavax compare to Pfizer?

Novavax (NASDAQ:NVAX) and Pfizer (NYSE:PFE) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Novavax presently has a consensus target price of $12.13, suggesting a potential upside of 36.54%. Pfizer has a consensus target price of $28.82, suggesting a potential upside of 10.06%. Given Novavax's higher probable upside, analysts clearly believe Novavax is more favorable than Pfizer.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novavax	4 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.10
Pfizer	2 Sell rating(s)	12 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.25

Pfizer has a net margin of 11.83% compared to Novavax's net margin of -14.73%. Pfizer's return on equity of 19.44% beat Novavax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novavax	-14.73%	-14.82%	1.23%
Pfizer	11.83%	19.44%	8.41%

Novavax has a beta of 2.45, indicating that its share price is 145% more volatile than the broader market. Comparatively, Pfizer has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

53.0% of Novavax shares are held by institutional investors. Comparatively, 68.4% of Pfizer shares are held by institutional investors. 1.6% of Novavax shares are held by company insiders. Comparatively, 0.6% of Pfizer shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Pfizer has higher revenue and earnings than Novavax. Novavax is trading at a lower price-to-earnings ratio than Pfizer, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novavax	$1.12B	1.30	$440.30M	-$0.58	N/A
Pfizer	$62.58B	2.39	$7.77B	$1.31	19.99

In the previous week, Pfizer had 89 more articles in the media than Novavax. MarketBeat recorded 97 mentions for Pfizer and 8 mentions for Novavax. Pfizer's average media sentiment score of 1.02 beat Novavax's score of 0.36 indicating that Pfizer is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novavax	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Pfizer	65 Very Positive mention(s)	8 Positive mention(s)	11 Neutral mention(s)	10 Negative mention(s)	2 Very Negative mention(s)	Positive

Summary

Pfizer beats Novavax on 13 of the 16 factors compared between the two stocks.

Get Novavax News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVAX vs. The Competition

Export

Metric	Novavax	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.46B	$3.40B	$6.74B	$12.07B
Dividend Yield	N/A	2.25%	2.67%	5.67%
P/E Ratio	-15.31	19.82	24.21	24.42
Price / Sales	1.30	305.69	512.04	109.94
Price / Cash	2.53	53.61	27.48	37.92
Price / Book	-11.24	8.32	10.66	6.83
Net Income	$440.30M	$23.94M	$3.57B	$337.67M
7 Day Performance	3.02%	1.84%	0.58%	1.17%
1 Month Performance	-1.99%	-0.04%	1.54%	3.16%
1 Year Performance	27.95%	44.82%	25.40%	30.58%

Novavax Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVAX Novavax	2.0469 of 5 stars	$8.88 flat	$12.13 +36.5%	+28.0%	$1.46B	$1.12B	N/A	1,990	Gap Up
MRNA Moderna	1.312 of 5 stars	$47.60 +0.3%	$36.60 -23.1%	+87.1%	$18.89B	$2.20B	N/A	4,700
OCGN Ocugen	2.1164 of 5 stars	$1.26 -1.6%	$9.50 +654.0%	+7.1%	$426.54M	$4.47M	N/A	80	Positive News
AZN Astrazeneca	4.5937 of 5 stars	$181.81 -2.2%	$205.33 +12.9%	N/A	$281.97B	$58.74B	27.30	96,100	Analyst Revision Gap Up
JNJ Johnson & Johnson	4.4088 of 5 stars	$232.17 -0.3%	$253.04 +9.0%	+53.3%	$558.89B	$94.19B	26.84	138,200	Trending News Insider Trade Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NVAX) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novavax (NVAX) Competitors